EP Patent

EP0981327B1 — Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Assigned to Warner Chilcott Ireland Ltd · Expires 2002-11-06 · 24y expired

What this patent protects

This invention relates to an intravaginal shell or core drug delivery device suitable for administration to female humans or animals comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or tes…

USPTO Abstract

This invention relates to an intravaginal shell or core drug delivery device suitable for administration to female humans or animals comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or testosterone precursor in a substantially zero-order pattern on a daily basis for at least three weeks. The device is intended to restore circulating testosterone levels to the normal physiol, range or to induce supratherapeutic testosterone levels.

Drugs covered by this patent

Patent Metadata

Patent number
EP0981327B1
Jurisdiction
EP
Classification
—
Expires
2002-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Warner Chilcott Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.